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Effectiveness of Direct-Acting Antiviral Therapy in Patients 
With Human Immunodeficiency Virus–Hepatitis C Virus 
Coinfection in Routine Clinical Care: A Multicenter Study
H. Nina Kim,1,  Robin M. Nance,1 Jessica S. Williams-Nguyen,2 J. A. Chris Delaney,2 Heidi M. Crane,1 Edward R. Cachay,3 Jeffrey Martin,4  
W. Christopher Mathews,3 Geetanjali Chander,5 Ricardo Franco,6 Christopher B. Hurt,7 Elvin H. Geng,4 Benigno Rodriguez,8 Richard D. Moore,5  
Michael S. Saag,6 and Mari M. Kitahata1; for the Centers for AIDS Research Network of Integrated Clinical Systems
Departments of 1Medicine and 2Epidemiology, University of Washington, Seattle, 3Department of Medicine, University of California, San Diego, 4Department of Medicine, University of California, 
San Francisco, 5Department of Medicine, Johns Hopkins University, Baltimore, Maryland, 6Department of Medicine, University of Alabama, Birmingham, 7Institute for Global Health & Infectious 
Diseases, University of North Carolina, Chapel Hill, and 8Department of Medicine, Case Western University, Cleveland, Ohio
Background. Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational 
studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health 
and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency 
virus (HIV)–hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions.
Methods. The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL 
≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We 
repeated this analysis after multiply imputing missing SVR values.
Results. Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, 
and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had gen-
otype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%–97.9%). Patients who 
were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, 
illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower 
SVR rate was early discontinuation (77.8%; 95% CI, 52.4%–93.6%). Similar results were seen in multiply imputed data sets.
Conclusions. Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The 
broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming 
and argues for widespread implementation of DAA therapy.
Key words. direct-acting antiviral; hepatitis C virus; HIV.
Chronic hepatitis C virus (HCV) infection is common among 
persons living with human immunodeficiency virus (HIV) 
infection (PLWH), with prevalence ranging from 15% to as 
high as 80% among those with a history of injection drug use 
(IDU) [1–3]. Coinfection with HIV can accelerate the progres-
sion of hepatic fibrosis in HCV and result in a more aggressive 
course of liver disease [4]. Liver disease remains a major cause 
of non–AIDS-related deaths among PLWH, with up to 80% of 
deaths attributable to HCV infection [5]. Although HCV treat-
ment should have high priority in PLWH, historically, uptake 
was limited due to poor treatment outcomes, adverse effects 
of interferon-based therapy, and comorbid conditions, such as 
psychiatric conditions and substance use disorders [6].
Interferon-free direct-acting antiviral (DAA) regimens have 
transformed the HCV treatment landscape since their introduction 
in 2014, with rates of sustained virologic response (SVR) exceeding 
90%. Clinical trial data suggest these safe, well-tolerated regimens 
have comparable high efficacy in HIV/HCV-coinfected and HCV-
monoinfected patients [7]. However, clinical trials of HIV/HCV-
coinfected patients were predominantly open-label studies with 
small numbers of participants and strict eligibility criteria. Patients 
with drug and alcohol use or medical and psychiatric disorders 
deemed by investigators to affect study adherence could have been 
excluded [8–10]. One Canadian study reported that only 6%–10% 
of their HIV/HCV-coinfected population would have been eligible 
for these trials [11].
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Observational studies of DAA therapy have reported com-
parable SVR rates among HIV/HCV-coinfected and HCV-
monoinfected patients [12–16], but less is known about 
real-world treatment outcomes in those with psychiatric dis-
orders or active substance use. DAA effectiveness needs to be 
examined specifically in these key high-risk patients who face 
ongoing barriers to HCV treatment [14, 17]. In this multicenter 
cohort study, we sought to evaluate the effectiveness of all-
oral combination DAA therapy among HIV/HCV-coinfected 
patients in routine clinical care, including those with psychoso-
cial comorbid conditions.
METHODS
Study Population
The Centers for AIDS Research Network of Integrated Clinical 
Systems (CNICS) is a dynamic prospective clinical cohort of 
adult PLWH receiving care at 8 participating academic sites 
across the United States. Comprehensive clinical data collected 
through electronic medical records and other institutional data 
systems undergo rigorous quality assessment, are harmonized 
in a central repository, and are updated on a quarterly basis 
[18]. The CNICS Data Management Core at the University of 
Washington works closely with investigators, clinicians and 
data teams at each site to ensure comprehensive capture of DAA 
treatment data. Institutional review boards at each site approved 
the cohort protocol, and the University of Washington institu-
tional review board approved this study.
Patients who received 1 of the following interferon-free DAA 
regimens (daclatasvir  plus  sofosbuvir, simeprevir  plus  sofos-
buvir, ledipasvir-sofosbuvir, ombitasvir-paritaprevir-ritona-
vir with dasabuvir, elbasvir-grazoprevir, sofosbuvir-velpatasvir) 
and completed therapy before the administrative censor date 
(4  months before the last available laboratory data for each 
CNICS site) were eligible for inclusion. For those who received 
multiple courses of DAA therapy, only the first course was 
examined. The choice of DAA was based on provider discretion 
and drug availability, as would occur in routine clinical care. 
Patients who received treatment as part of a clinical trial or 
before the respective Food and Drug Administration approval 
date of these drugs were excluded. Regimens with concurrent 
ribavirin were noted and included in the analysis.
Outcome Measures
The primary end point was SVR, defined as an HCV RNA level 
that was not detected or <25 IU/mL ≥10 weeks after the end 
of treatment. RNA reported below the limit of detection was 
defined as the median of 0 and the limit of detection. Due to 
variability in the timing of testing seen in a clinical setting, we 
included HCV RNA levels collected 2 weeks earlier than the 
standard 12 weeks after treatment in our primary analysis (as 
has previously been done [12, 19]); RNA measurements beyond 
week 4–8 of treatment have high correlation with SVR at 12 
weeks  (SVR12) [20]. We also examined a strict definition of 
SVR12 in a secondary analysis. Treatment failure (among those 
undergoing posttreatment testing) was defined as HCV RNA 
≥25 IU/mL ≥4 weeks after completion of therapy. Viral relapse 
was defined as ≥1 HCV RNA measurement <25 IU/mL during 
and/or at end of treatment with subsequent detectable HCV 
RNA after treatment in the absence of SVR.
Patient Characteristics
Demographic characteristics included sex, race/ethnicity, HIV 
transmission risk category, and age at baseline. The CD4 cell 
count, HIV RNA, HCV RNA, HCV genotype and fibrosis-4 
(FIB-4) components (platelet count and serum alanine and 
aspartate aminotransferase levels) represented the most recent 
values before the DAA start, and HIV RNA measurements were 
restricted to within 1 year before DAA start. Chronic hepatitis 
B virus coinfection was defined as the presence of either hep-
atitis B surface antigen or detectable hepatitis B virus DNA. 
Cirrhosis was defined as an FIB-4 index >3.25 [21]. Patients 
who received interferon (pegylated interferon alfa-2a or alfa-2b 
or standard interferon) and/or ribavirin before the DAA initi-
ation date were noted to have treatment experience. Diabetes 
mellitus was defined as a diagnosis of diabetes mellitus recorded 
by the treating clinician and the use of diabetes-related medica-
tion, use of diabetes-specific medication, or hemoglobin A1C 
measurement ≥6.5%. Obesity was defined as a body mass index 
>30 kg/m2.
Mental health disorder was considered present if the diag-
nosis was recorded any time by the treating clinician before the 
DAA start date, and was examined separately as: (1) depression 
and/or anxiety or (2) psychotic disorders (psychosis, schizo-
phrenia, schizoaffective disorder). Illicit substance use included 
diagnoses of methamphetamine, cocaine or opiate use disorder 
and alcohol use disorder included diagnoses of alcohol abuse or 
dependence [22], all recorded before DAA start. We also eval-
uated current substance use among patients who completed a 
patient-reported outcome (PRO) clinical assessment, described 
elsewhere [23], using the latest date from 1 year before DAA start 
to the end of DAA treatment. At-risk alcohol use was defined as 
an Alcohol Use Disorders Identification Test (AUDIT-C) score 
≥4 for men and ≥3 for women [24]. Illicit drug use was defined 
as current use of cocaine, opiates, or methamphetamines noted 
on the Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST) questionnaire [25]. Early treatment discontin-
uation (ETD) was defined as duration of therapy (difference 
between end and start dates) <70  days (<10 weeks), among 
patients who received <120 days of therapy.
Statistical Analysis
In the main analysis, SVR rates were calculated as the propor-
tion of patients with SVR among those who underwent SVR 
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assessment, in a modified intent-to-treat analysis. We com-
pared baseline characteristics of patients with or without SVR 
assessment, using the Mann-Whitney test for continuous and 
the χ2 test for categorical variables. We calculated SVR rates and 
95% confidence intervals (CIs) for the overall cohort as well as 
for subgroups of patients defined by prespecified characteris-
tics. The χ2 test was also used to assess differences in SVR rates 
between select subgroups. Analyses were conducted using Stata 
software, version 14.2.
To evaluate whether our complete case analysis was subject 
to bias, missing values in SVR and other covariates were mul-
tiply imputed with chained equations using fully conditional 
specification with R package mice (R software; version 3.4.4). 
Imputation models relied on classification and regression trees 
[26] and incorporated key covariates as well as treatment dura-
tion and follow-up. This process yielded 100 complete data sets. 
For each complete data set, SVR rates and CIs were calculated, 
and resulting inferences were pooled using Rubin’s rules [27].
RESULTS
In total, 642 patients with HIV/HCV coinfection received 1 of 
the specified DAA regimens from February 2014 to October 
2017. Of these, 536 underwent posttreatment SVR assessment 
as part of routine clinical care and comprised the main analytic 
cohort. The patients’ median age was 55 years; 79% were men, 
and 59% were black (Table 1). The distribution of HIV risk fac-
tor categories was as follows: 25% men who have sex with men 
(MSM), 42% IDU, and 14% MSM and IDU. The median CD4 
cell count was 540/μL; 496 (98%) of 508 patients who had an 
HIV viral load assessment within 1 year before starting DAA 
therapy had an HIV viral load <200 copies/mL. Among the 
467 patients (87%) receiving antiretroviral therapy at baseline, 
>70% had regimens that contained integrase strand transfer 
inhibitors. Compared with other HIV/HCV-coinfected patients 
in care at this time, the study cohort was similar in age, sex, 
race, HIV risk factor, baseline CD4 cell count, and prevalence 
of mental health and substance use diagnoses.
Among the 507 patients with HCV genotype results available, 
nearly all (96%) had genotype 1 infection; 69% had genotype 
1a, 24% had genotype 1b, and 3% had no subtyping. Cirrhosis 
was present in 24%, and a baseline HCV RNA level >6 million 
IU/mL was observed in 21%. Prior treatment experience with 
interferon-based therapy was documented in 17%.
Consistent with clinical practice during this time frame, 
80% of patients (n  =  432) received ledipasvir-sofosbuvir, and 
the rest received simeprevir  plus  sofosbuvir (n  =  41), sofosbu-
vir-velpatasvir (n  =  24), daclatasvir  plus  sofosbuvir (n  =  14), 
ombitasvir-paritaprevir-ritonavir plus dasabuvir (n = 13), or elb-
asvir-grazoprevir (n = 12). Only 6% of patients (n = 33) received 
ribavirin concurrently; a third of these patients received ombi-
tasvir-paritaprevir-ritonavir  plus  dasabuvir with the ribavirin, 
as might be expected, given the predominance of genotype 1a 
infection.
The duration of therapy clustered predominantly around 12 
weeks (84 days; interquartile range, 84–85 days) and 24 weeks 
(168 days; 167–168 days). Among the 476 patients with a treat-
ment duration <120  days, only 18 (3.8%) discontinued treat-
ment early (before 70 days or 10 weeks), with a median duration 
of 45 days (range 19–61 days).
The 106 patient (16.5%) who did not have SVR results did not 
differ from the study cohort in age, sex, race, HIV risk factor, 
or key clinical characteristics (proportion with CD4 cell count 
<200/μL , HIV RNA <200 copies/mL, FIB-4 index >3.25, and 
mental health and substance use diagnoses). The duration of 
DAA treatment in these patients was comparable to that in the 
study cohort, but they had fewer HCV measurements during 
treatment (median, 1 vs 2, respectively) and shorter median 
follow-up after DAA start (227 vs 673  days). Among the 106 
patients without SVR measurements, 52 (49%) had HCV RNA 
not detected or <25 IU/mL at the end of treatment (n = 30) or 
≥4 weeks after treatment (n = 22).
Sustained Virologic Response
Overall, SVR occurred in 517 patients, for an SVR rate of 
96.5% (95% CI, 94.5%–97.9%) (Table 2). All 19 patients with-
out SVR were confirmed to have treatment failure and evidence 
of detectable HCV RNA >25 IU/mL ≥4 weeks after the end 
of DAA therapy. Of these, 13 had viral relapse, 5 had missing 
HCV RNA measurements during treatment, and 1 had a sin-
gle low-detectable HCV RNA measurement during treatment 
before meeting criteria for treatment failure.
SVR rates were examined within key subgroups. Among 
HCV-specific factors, we found no significant difference by 
genotype (or subtype), but genotype other than 1 was present 
in only 4% of those treated. Notably, patients who had potential 
risk factors for suboptimal treatment response, including high 
baseline HCV RNA (>6 million IU/mL), cirrhosis (FIB-4 index 
>3.25), prior treatment experience (pegylated interferon with 
or without ribavirin), obesity (body mass index >30 kg/m2), or 
diabetes mellitus all had high SVR rates, exceeding 95%. Black 
patients comprised the majority of our cohort and had an SVR 
rate of 97.2%.
We observed no statistically significant difference in SVR 
rates between groups stratified by HIV-specific factors, includ-
ing baseline CD4 cell count <200/μL (92.1%) or ≥200/μL 
(96.8%; P = .13). SVR was achieved in all 13 patients with base-
line HIV RNA ≥200 copies/mL.
We also observed high SVR rates in those with a history 
of mental health or substance use disorders. Among patients 
with a diagnosis of depression and/or anxiety (n = 374), 96.3% 
had SVR. Among those with a diagnosis of a psychotic disor-
der (n = 65), 95.4% had SVR. Patients with a history of either 
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illicit drug use or alcohol use disorder before DAA initiation 
also achieved high SVR rates of 96.4% and 96.8% respectively. 
Although mental health and substance use disorders can co-oc-
cur with potentially greater comorbidity, we observed similar 
high SVR rates in the subset of patients with depression and/or 
anxiety and either illicit drug use or alcohol use disorder.
We also evaluated current substance use among the 334 
patients (62%) who completed a PRO survey. Among the 
40 (12%) who endorsed current illicit drug use, 97.5% (95% 
CI, 86.8%–99.9%) had SVR, as did all 37 (11%) of those who 
reported current at-risk drinking by AUDIT-C.
The only factor associated with lower SVR rates was ETD. 
SVR rate was 77.8% (95% CI, 52.4%–93.6%) among the 18 indi-
viduals who had ETD, compared with 96.7% among those who 
did not (P < .001). Among these 18 patients, 4 experienced treat-
ment failure; their duration of therapy ranged from 4 to 6 weeks 
(26–41 days). In contrast, of the 14 patients with ETD who had 
SVR despite a shortened course of treatment, only 5 (36%) had 
durations <6 weeks (P = .02). We did not identify any baseline 
factors (demographic, HIV specific. or liver related) that distin-
guished patients with ETD from the rest of our cohort.
Secondary Analyses
When we evaluated the SVR outcome more strictly as HCV 
RNA <25 IU/mL ≥12 weeks after treatment discontinuation, 
our findings were similar for the 514 participants who had an 
assessment of SVR12, with a high overall SVR rate of 96.5% 
(95% CI, 94.5%–97.9%).
In addition, we examined the entire cohort of 642 patients, 
including the 106 who with missing SVR assessments. When 
we used multiple imputation to derive missing SVR values using 
baseline as well as during-treatment characteristics including 
duration of treatment and follow-up, the pooled SVR rate was 
95.9% (95% CI, 94.1%–97.6%), similar to the observed SVR rate 
of 96.5% in the main cohort (Supplementary Table 1). We found a 
similarly lower SVR rate of 75% (95% 55, 95.1) among those with 
ETD. SVR estimates for key subgroups, including those with men-
tal health or substance use, disorders were also comparable.
DISCUSSION
In this multicenter study of HIV/HCV-coinfected patients 
who received DAA therapy as part of routine clinical care, we 
observed a high overall SVR rate of 96.5%. This cohort included 
a wide spectrum of patients, some with poor prognostic features 
for treatment outcome, including advanced fibrosis, high base-
line HCV viral level, and prior treatment experience. Response 
rates were consistently high across the subgroups evaluated, 
including those with mental health and substance use disorders, 
generally exceeding 95%. We observed a low ETD rate, with 
only 3.8% stopping therapy before 10 weeks, supporting the 
excellent safety profile and tolerability of these agents. The only 
factor associated with treatment failure in our study was ETD.
Table 1. Baseline Characteristics of 536 Patients With Human 
Immunodeficiency Virus–Hepatitis C Virus Coinfection Treated with 
Interferon-Free Direct-Acting Antiviral Regimens, 2014–2017
Characteristic Patients, No. (%)a
Age, median (range), y 55 (26–75)
Male sex 426 (79)
Race/ethnicity  
 White 170 (32)
 Black 315 (59)
 Hispanic 34 (6)
 Other 15 (3)
HIV risk factor category  
 MSM 132 (25)
 IDU 228 (42)
 MSM and IDU 74 (14)
 Heterosexual 85 (16)
 Other/unknown 11 (2)/6 (1)
CD4 cell count  
 <200/μL 38 (7)
 200–499/μL 205 (38)
 ≥500/μL 293 (55)
Antiretroviral therapyb 467 (87)
 Tenofovir disoproxil fumarate 270 (58)
 Dolutegravir 218 (47)
 Abacavir 165 (35)
 Raltegravir 95 (20)
 Darunavir 91 (19)
 Efavirenz 60 (13)
 Rilpivirine 56 (12)
 Atazanavir 40 (8.6)
 Cobicistat-elvitegravir 25 (5.4)
HIV RNA <200 copies/mLc 496 (98)
Chronic hepatitis B 54 (10)
Body mass index >30 kg/m2 131 (25)
Diabetes mellitusd 105 (20)
HCV RNA >6 million IU/mL 111 (21)
Fibrosis-4 index >3.25 128 (24)
Prior treatment experience 90 (17)
HCV genotype (n = 507)  
 1a 352 (69)
 1b 120 (24)
 1 not subtyped 15 (3)
 2 7 (1)
 3 9 (2)
 4 4 (1)
DAA regimen  
 Ledipasvir-sofosbuvir 432 (81)
 Simeprevir + sofosbuvir 41 (8)
 Sofosbuvir-velpatasvir 24 (4)
 Daclatasvir + sofosbuvir 14 (3)
 Ombitasvir-paritaprevir-ritonavir + dasabuvir 13 (2)
 Elbasvir-grazoprevir 12 (2)
 Concurrent ribavirin 33 (6)
Mental health disorder  
 Depression and/or anxiety 374 (70)
 Psychotic condition 65 (12)
Substance use disorder  
 Illicit drugs (amphetamine, cocaine, opiate) 251 (47)
 At-risk alcohol 185 (35)
Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; HIV, human immunodefi-
ciency virus; IDU, injection drug use; MSM, men who have sex with men.
aData represent no. (%) of patients unless otherwise specified. 
bAntiretroviral therapy categories represent the no. (%) of patients with these agents in 
their regimen among the 467 patients receiving antiretroviral therapy, recorded before DAA 
start. 
cAmong the 508 patients who had HIV RNA level assessed within 1 year of DAA start. The 
CD4 cell count, HIV and HCV viral levels, and fibrosis-4 index represented the most recent 
values before the DAA start date. 
dDiabetes mellitus was defined as a diagnosis of diabetes mellitus and use of diabetes-re-
lated medication, use of diabetes-specific medication, or hemoglobin A1C ≥6.5%.
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Our findings are consistent with the high SVR rates reported 
in registration trials of DAA agents and suggest not only that 
these treatments are quite robust in real-world settings but that 
HIV status does not adversely affect treatment outcomes with 
all-oral regimens as it had with interferon-based therapy [1]. 
Notably, nearly all of our cohort had evidence of HIV viral sup-
pression during antiretroviral therapy [28] before the start of 
DAA therapy, and the median CD4 cell count exceeded 500/
μL, similar to findings among subjects in the DAA trials [8–10]. 
Other large-cohort studies in the Veterans Administration sys-
tem and Europe have demonstrated high rates of effectiveness 
with DAA therapy in HIV/HCV-coinfected patients similar 
to that of HCV-monoinfected patients [12, 13, 16]. Together, 
these data support the shift away from considering patients with 
HIV-HCV coinfection a special “treatment-refractory” popula-
tion [7].
Clinician-recorded mental health and substance use disor-
ders were highly prevalent in our cohort, as might be expected 
of a real-world HIV/HCV-coinfected population [29], and did 
not seem to be associated with reduced likelihood of treatment 
success. We observed SVR rates exceeding 95% in patients with 
depression, anxiety, psychotic disorders, illicit drug use, or 
Table 2. Sustained Virologic Response Rates in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection Treated with Interferon-Free 
Direct-Acting Antiviral Regimens, Overall and by Key Subgroups
Group Patients, No. (%) SVR Rate (95% CI), %
Overall 536 (100) 96.5 (94.5–97.9)
DAA regimen   
 Ledipasvir-sofosbuvir 432 (81) 97.0 (94.9–98.4)
 Simeprevir + sofosbuvir 41 (8) 95.1 (83.5–99.4)
 Sofosbuvir-velpatasvir 24 (4) 87.5 (67.6–97.3)
 Daclatasvir + sofsobuvir 14 (3) 92.9 (66.1–99.8)
 Ombitasvir-paritaprevir-ritonavir + dasabuvir 13 (2) 100 (75.3–100)a
 Elbasvir-grazoprevir 12 (2) 100 (73.5–100)a
Ledipasvir-sofosbuvir by duration   
 12 wk 380 (71) 96.6 (94.2–98.2)
 24 wk 52 (10) 100 (93.2–100)a
Genotype   
 1a 352 (66) 96.3 (93.8–98.0
 1b 120 (22) 96.7 (91.7–99.1)
 1 not subtyped 15 (3) 93.3 (68.1–99.8)
 2 7 (1) 85.7 (42.1–99.6)
 3 9 (2) 100 (66.4–100)a
 4 4 (1) 100 (39.8–100)a
 Missing 29 (5) 100 (88.1–100)a
Age >50 y 385 (72) 96.6 (94.3–98.2)
Female sex 110 (21) 97.3 (92.2–99.4)
Black 315 (59) 97.1 (94.6–98.7)
Body mass index >30 kg/m2 131 (24) 97.7 (93.5–99.5)
Diabetes mellitus 105 (20) 96.2 (90.5–99.0)
Treatment experienced 90 (17) 98.9 (94.0–99.9)
Fibrosis-4 index >3.25 128 (24) 96.9 (92.2–99.1)
HCV RNA >6 million IU/mL 111 (21) 95.5 (89.8–98.5)
CD4 cell count <200/μL 38 (7) 92.1 (78.6–98.3)
Early treatment discontinuationb 18 (3) 77.8 (52.4–93.6)
Mental health disorderc   
 Depression and/or anxiety 374 (70) 96.3 (93.8–97.9)
 Psychotic condition 65 (12) 95.4 (87.1–99.0)
Substance use disorderc   
 Illicit drug use (amphetamines, cocaine, opiates) 252 (47) 96.4 (93.3–98.4)
 At-risk alcohol use 185 (35) 96.8 (93.1–98.8)
Combined mental health and substance use disorderc   
 Depression and/or anxiety and illicit drug use 211 (39) 96.2 (92.7–98.3)
 Depression and/or anxiety and at-risk alcohol use 157 (29) 96.2 (91.9–98.6)
Abbreviations: CI, confidence interval; DAA, direct-acting antiviral; HCV, hepatitis C virus; SVR, sustained virologic response.
aOne-sided 97.5% CI.
bDuration <70 days among patients with treatment duration of <120 days.
cMental health and substance use diagnoses recorded by treating clinician before DAA start.
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alcohol use disorders. Moreover, those patients who endorsed 
current at-risk alcohol and drug use on PRO surveys also did 
very well. These conditions were historically among the leading 
reasons for treatment ineligibility in the interferon era [30]. We 
did not assess current IDU, but data from the interferon and 
DAA eras suggest that recent IDU does not impede treatment 
success [31–33]. The majority of states in the United States cur-
rently restrict DAA access to Medicaid beneficiaries with some 
form of sobriety restriction, mandating abstinence from drugs 
and/or alcohol for a specified period of time [34]. Our find-
ings support the feasibility and success of DAA therapy among 
persons who are  actively using drugs or in recovery. Because 
provider biases and structural barriers continue to complicate 
the care of persons who use or inject drugs (a group for which 
DAA treatment must be considered if HCV elimination is to be 
achieved [35]), it is critical to build an evidence base supporting 
widespread treatment in this population [17].
All of the CNICS sites that contributed participants to this 
analysis used a “medical home” model of DAA treatment deliv-
ery during our study time frame. That is, HCV treatment was 
not delegated to specialists outside the HIV clinic, as was typ-
ically done in the interferon-based era. This model of primary 
HCV care has been shown to be highly successful in a variety 
of care settings [15, 36–38] and may facilitate treatment uptake. 
However, barriers to successful DAA delivery persist even 
within well-resourced primary care clinics [39], due to lack of 
engagement and retention in care.
It is important to note that this represents the first wave of 
interferon-free DAA-treated individuals who were, even in the 
real-world setting, not wholly unselected, as their providers 
perhaps preferentially elected to treat them over other patients. 
It remains to be seen whether these DAAs are robust enough to 
perform as well in patients who were delayed in getting treated 
compared with their peers.
Limitations to our study warrant further discussion. 
Observational studies are vulnerable to misclassification and 
incomplete data. Unlike in a clinical trial, we were not able to pro-
vide data on adherence, adverse events, or reasons for ETD. We 
were unable to capture decompensated cirrhosis reliably in our 
data set or stratify based on this key characteristic. We had very 
few non–genotype 1 patients, so conclusions outside of genotype 
1 may not be generalizable. The number of patients with active 
substance use by PRO survey was also small, so findings should 
be interpreted cautiously. Our use of mental health and substance 
use diagnoses may also suboptimally represent active conditions. 
We also opted to evaluate DAA effectiveness as a modi-
fied intent-to-treat analysis of those patients who had an SVR 
assessment, rather than including all those who had no HCV 
RNA assessment and considering them as treatment failures. 
Although a full intent-to-treat analysis would reflect a more 
conservative estimate, this approach could also underestimate 
true effectiveness. It is possible that the patients who lacked 
SVR assessments represented those with inadequate adherence, 
loss to follow-up, or other poor prognostic indicators for treat-
ment success, but the majority of these patients had ≥1 RNA 
measurement during treatment, and nearly half were undetect-
able at or after the end of therapy, which suggests engagement in 
care during treatment. Their baseline characteristics were also 
similar to those in patients who underwent SVR assessments. 
Thus, these patients may represent those who had not yet had 
their follow-up HCV viral testing, rather than actual treatment 
dropouts. Results of sensitivity analysis suggest that the exclu-
sion of such patients was not likely to have introduced signifi-
cant bias. Finally, there were too few individuals with treatment 
failure to evaluate predictors of DAA nonresponse.
Our study represents a large multicenter examination of DAA 
therapy of HIV/HCV-coinfected patients in routine clinical care. 
The broad treatment success we observed with DAAs across this 
diverse group of patients, including those with a variety of comor-
bid psychosocial conditions, is highly affirming and argues for 
the widespread implementation of DAA therapy. Further work 
needs to focus on optimizing HCV screening, linkage, and treat-
ment uptake on a population-based level to overcome the multi-
level barriers to HCV elimination. The lessons we have learned 
in reducing HIV-related morbidity and mortality rates should 
enhance care delivery for all persons living with HCV infection.
Supplementary Data
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the posted materials are not copyedited and are the sole responsibility of 
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